Tech Company Financing Transactions

Nimbus Therapeutics Funding Round

Access Industries, Atlas Venture and Bain Capital Life Sciences participated in a $125 million capital raise for Nimbus Therapeutics. The funding round was announced by the company on 9/12/2022.

Transaction Overview

Company Name
Nimbus Therapeutics
Announced On
9/12/2022
Transaction Type
Venture Equity
Amount
$125,000,000
Round
Undisclosed
Investors

Access Industries

Atlas Venture (Bruce Booth)

Bain Capital Life Sciences

BVF Partners

private investors (Bill Gates)

Lightstone Ventures (Chris Christoffersen)

Pfizer Venture Investments

RA Capital

SR One Capital Management (Kent Gossett)

SV Health Investors

Proceeds Purpose
The financing will support the ongoing Phase 1/2 clinical trials of NDI-101150, Nimbus' hematopoietic progenitor kinase 1 (HPK1) inhibitor, in patients with solid tumors, as well as preclinical development of programs targeting Casitas B-lineage lymphoma b (Cbl-b) and Werner syndrome helicase (WRN), along with ongoing discovery efforts across a range of targets.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
130 Prospect St. 301
Cambridge, MA 02139
USA
Phone
(857) 999-2009
Website
www.nimbustx.com
Email Address
[email protected]
Overview
Nimbus Therapeutics is a biotechnology company that is pioneering a new computational technology-driven paradigm to rapidly advance a diverse pipeline of novel small molecule product candidates into clinical development.
Profile
Nimbus Therapeutics LinkedIn Company Profile
Social Media
Nimbus Therapeutics Company Twitter Account
Company News
Nimbus Therapeutics News
Facebook
Nimbus Therapeutics on Facebook
YouTube
Nimbus Therapeutics on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Jeb Keiper
  Jeb Keiper LinkedIn Profile  Jeb Keiper Twitter Account  Jeb Keiper News  Jeb Keiper on Facebook
Chief Financial Officer
Holly Whittemore
  Holly Whittemore LinkedIn Profile  Holly Whittemore Twitter Account  Holly Whittemore News  Holly Whittemore on Facebook
Chief Scientific Officer
Peter Tummino
  Peter Tummino LinkedIn Profile  Peter Tummino Twitter Account  Peter Tummino News  Peter Tummino on Facebook
Vice President
Scott Edmondson
  Scott Edmondson LinkedIn Profile  Scott Edmondson Twitter Account  Scott Edmondson News  Scott Edmondson on Facebook
Vice President
Christine Loh
  Christine Loh LinkedIn Profile  Christine Loh Twitter Account  Christine Loh News  Christine Loh on Facebook
VP - Bus. Development
Abbas Kazimi
  Abbas Kazimi LinkedIn Profile  Abbas Kazimi Twitter Account  Abbas Kazimi News  Abbas Kazimi on Facebook
VP - Human Resources
Erin Cowhig
  Erin Cowhig LinkedIn Profile  Erin Cowhig Twitter Account  Erin Cowhig News  Erin Cowhig on Facebook

 

 

Browse more venture capital transactions:

Prev: 9/12/2022: PurpleLab venture capital transaction
Next: 9/12/2022: Forward venture capital transaction

 

Share this article

 

About Our Venture Capital Transactions Database

We report on funding rounds that are announced publicly. VC transactions on this site are derived from company press releases and news coverage. The information is sourced from VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.